CONDENSED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 10,813	$ 20,272	$ 38,606	$ 22,207
Operating expenses:
Cost of goods sold	3,055		5,136
Research and development	24,691	15,514	65,869	59,870
General and administrative	6,912	5,882	23,829	17,898
Total operating expenses	34,658	21,396	94,834	77,768
Operating loss	(23,845)	(1,124)	(56,228)	(55,561)
Other income, net	665	111	1,093	502
Net loss	$ (23,180)	$ (1,013)	$ (55,135)	$ (55,059)
Net loss per share:
Basic	$ (0.43)	$ (0.02)	$ (1.03)	$ (1.10)
Diluted	$ (0.43)	$ (0.02)	$ (1.03)	$ (1.10)
Weighted average shares:
Basic	53,726,123	50,114,710	53,616,753	50,031,615
Diluted	53,726,123	50,114,710	53,616,753	50,031,615
Other comprehensive income (loss), net of tax of $0:
Change in unrealized gains (losses) on available-for-sale marketable securities	$ (101)	$ 6	$ (1,790)	$ (72)
Total comprehensive loss	(23,281)	(1,007)	(56,925)	(55,131)
Collaborative Revenue
Revenue:
Total revenue	7,443		15,446	706
License and Milestone Fees
Revenue:
Total revenue		20,031	15,000	21,223
Commercial Supply Revenue
Revenue:
Total revenue	$ 3,370		$ 8,160
Clinical Compound Revenue
Revenue:
Total revenue		$ 241		$ 278